SG158112A1 - Hepatocyte growth factor (hgf) binding proteins - Google Patents

Hepatocyte growth factor (hgf) binding proteins

Info

Publication number
SG158112A1
SG158112A1 SG200908089-6A SG2009080896A SG158112A1 SG 158112 A1 SG158112 A1 SG 158112A1 SG 2009080896 A SG2009080896 A SG 2009080896A SG 158112 A1 SG158112 A1 SG 158112A1
Authority
SG
Singapore
Prior art keywords
hgf
binding proteins
growth factor
hepatocyte growth
activity
Prior art date
Application number
SG200908089-6A
Other languages
English (en)
Inventor
William M Winston
S Kirk Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Publication of SG158112A1 publication Critical patent/SG158112A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SG200908089-6A 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins SG158112A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21

Publications (1)

Publication Number Publication Date
SG158112A1 true SG158112A1 (en) 2010-01-29

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908089-6A SG158112A1 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Country Status (20)

Country Link
US (5) US7649083B2 (enExample)
EP (2) EP2361934A3 (enExample)
JP (3) JP4686634B2 (enExample)
KR (1) KR101196060B1 (enExample)
AR (1) AR061171A1 (enExample)
AT (1) ATE495195T1 (enExample)
AU (1) AU2007254942B2 (enExample)
BR (1) BRPI0712222B1 (enExample)
CA (1) CA2654025C (enExample)
CY (1) CY1111714T1 (enExample)
DE (1) DE602007011923D1 (enExample)
DK (1) DK2027156T3 (enExample)
IL (2) IL195037A (enExample)
MX (1) MX2008014829A (enExample)
NO (1) NO345476B1 (enExample)
NZ (1) NZ573818A (enExample)
PL (1) PL2027156T3 (enExample)
PT (1) PT2027156E (enExample)
SG (1) SG158112A1 (enExample)
WO (1) WO2007143090A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
PL2027156T3 (pl) * 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP4588519A3 (en) * 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
AU2009255305B2 (en) 2008-05-29 2014-10-30 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
AU2012304362A1 (en) 2011-09-09 2014-03-06 Amgen Inc. Use of c-Met protein for predicting the efficacy of anti-hepatocyte growth factor ("HGF") antibodies in esophageal and gastric cancer patients
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201438737A (zh) * 2013-03-14 2014-10-16 Alder Biopharmaceuticals Inc Ｈｇｆ抗體之治療用途
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US20170247437A1 (en) * 2014-08-15 2017-08-31 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
JP2022543555A (ja) 2019-08-12 2022-10-13 インテアールエヌエー テクノロジーズ ビー．ヴイ． ｍｉＲＮＡ－１９３ａに関する新たな処置
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
PL2027156T3 (pl) 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
IL195037A (en) 2015-08-31
WO2007143090A2 (en) 2007-12-13
BRPI0712222A2 (pt) 2012-01-10
US7649083B2 (en) 2010-01-19
AU2007254942A8 (en) 2009-02-05
ATE495195T1 (de) 2011-01-15
KR101196060B1 (ko) 2012-11-01
CA2654025A1 (en) 2007-12-13
NZ573818A (en) 2011-09-30
HK1129395A1 (en) 2009-11-27
BRPI0712222B1 (pt) 2021-10-13
IL195037A0 (en) 2011-08-01
EP2027156B1 (en) 2011-01-12
CY1111714T1 (el) 2015-10-07
EP2027156A2 (en) 2009-02-25
KR20090027226A (ko) 2009-03-16
NO20085421L (no) 2009-02-27
CA2654025C (en) 2016-08-02
PL2027156T3 (pl) 2011-06-30
US7943344B2 (en) 2011-05-17
US8273355B2 (en) 2012-09-25
EP2027156B9 (en) 2011-03-30
WO2007143090A3 (en) 2008-03-13
JP2011072318A (ja) 2011-04-14
EP2361934A3 (en) 2011-11-02
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
AU2007254942A1 (en) 2007-12-13
IL219654A0 (en) 2012-06-28
US20080108565A1 (en) 2008-05-08
JP4686634B2 (ja) 2011-05-25
JP2013090632A (ja) 2013-05-16
PT2027156E (pt) 2011-04-18
US8580930B2 (en) 2013-11-12
NO345476B1 (no) 2021-02-22
DE602007011923D1 (de) 2011-02-24
US20140178935A1 (en) 2014-06-26
US20100173362A1 (en) 2010-07-08
EP2361934A2 (en) 2011-08-31
US9096664B2 (en) 2015-08-04
JP2009539347A (ja) 2009-11-19
MX2008014829A (es) 2009-01-29
US20110229462A1 (en) 2011-09-22
US20130203963A1 (en) 2013-08-08
JP5735476B2 (ja) 2015-06-17
DK2027156T3 (da) 2011-04-26
AU2007254942B2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2008065378A3 (en) Binding members for interleukin-6
MX2007015487A (es) Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
JO2576B1 (en) Antibodies
NZ599875A (en) Human il-23 antigen binding proteins
MY185858A (en) Specific binding proteins and uses thereof
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
NZ606294A (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
TW200732347A (en) VEGF analogs and methods of use
TW200833692A (en) Triazolopyridazine protein kinase modulators
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
NZ592973A (en) Compositions and methods of using angiopoietin-like 4 protein
MY160041A (en) Compositions and methods for treating parasitic infections
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
WO2013061083A3 (en) Therapeutic agents and uses thereof
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer